Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.40)
# 3,833
Out of 4,762 analysts
43
Total ratings
17.24%
Success rate
-29.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $12.86 | +1.17% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $1.83 | - | 2 | Mar 7, 2025 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $13.50 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $42.09 | - | 4 | Feb 19, 2025 | |
| CDTX Cidara Therapeutics | Assumes: Overweight | n/a | $22.46 | - | 1 | Jan 27, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $68.26 | - | 6 | Jan 10, 2025 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $31.61 | - | 4 | Dec 18, 2024 | |
| TNGX Tango Therapeutics | Reiterates: Overweight | n/a | $1.84 | - | 3 | Dec 5, 2024 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.70 | - | 3 | Nov 14, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $33.46 | +186.94% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.74 | - | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.53 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.04 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $139.67 | +109.06% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $500.82 | -26.12% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.42 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.46 | - | 1 | May 30, 2017 |
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $12.86
Upside: +1.17%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.83
Upside: -
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $13.50
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $42.09
Upside: -
Cidara Therapeutics
Jan 27, 2025
Assumes: Overweight
Price Target: n/a
Current: $22.46
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $68.26
Upside: -
Agios Pharmaceuticals
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.61
Upside: -
Tango Therapeutics
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.84
Upside: -
Alumis
Nov 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.70
Upside: -
Avidity Biosciences
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $33.46
Upside: +186.94%
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.74
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.53
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.04
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $139.67
Upside: +109.06%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $500.82
Upside: -26.12%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.46
Upside: -